NICE Likely To Lose Cost-Watchdog Status By 2013
The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.
You may also be interested in...
The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence
NICE Rejects Leukemia Drugs On Eve Of Conference That Likely Will Debate Cancer Policies, NICE's Future
A lack of good clinical trial data on the use of Sprycel, high-dose Glivec and Tasigna in imatinib-resistant chronic myeloid leukemia patients leads to rejection by NICE in a draft guidance.
The U.K.’s National Institute for Health and Clinical Excellence launched a new section within its website dedicated to providing health care providers with evidence-based guidelines. The addition comes in anticipation of the proposed change in NICE’s role, which would emphasize promoting best practices rather than determining the cost-effectiveness of drugs.